Genotyping Market Report 2026

The genotyping market size has grown rapidly in recent years. It will grow from $26.55 billion in 2025 to $31.26 billion in 2026 at a compound annual growth rate (CAGR) of 17.7%. The growth in the historic period can be attributed to advances in molecular biology, early genetic variation studies, growth of diagnostic laboratories, academic research adoption, development of microarray technologies.

The genotyping market size is expected to see rapid growth in the next few years. It will grow to $60.54 billion in 2030 at a compound annual growth rate (CAGR) of 18%. The growth in the forecast period can be attributed to expansion of precision medicine, growth in crop genetics research, declining genotyping costs, increased biopharma investment, integration with clinical diagnostics. Major trends in the forecast period include growing use of genotyping in personalized medicine, expansion of genotyping in agricultural biotechnology, rising adoption of high-throughput genotyping platforms, increased demand for pharmacogenomics applications, integration of bioinformatics in genotyping workflows.

The growing demand for genetic testing is expected to drive the expansion of the genotyping market in the coming years. Genetic testing, also known as DNA or molecular testing, involves analyzing an individual’s DNA to detect variations, mutations, or alterations in their genetic code. Genotyping is an essential component of genetic testing, providing detailed information about an individual’s specific genetic variations. For example, in February 2025, NHS England, a UK-based government healthcare agency, reported that the NHS Genomic Medicine Service conducted over 810,000 genomic tests for patients across the life course in England in 2024. This represents an 8% increase compared to 2023 and reflects a consistent year-on-year growth since the establishment of the NHS Genomic Medicine Service. Consequently, the rising demand for genetic testing is fueling growth in the genotyping market.

Key companies in the genotyping market are focusing on the development of innovative solutions, such as high-coverage whole genome sequencing, to enhance genetic analysis. High-coverage whole genome sequencing (WGS) is an advanced technique that examines an individual’s entire genome with a high degree of coverage, enabling comprehensive variant detection. For instance, in September 2023, CD Genomics, a US-based provider of genomics, transcriptomics, and bioinformatics services, launched its Genotyping by Sequencing (GBS) service. This service combines next-generation sequencing with restriction enzyme digestion to deliver high-throughput, cost-effective genome-wide SNP genotyping for large sample sets. CD Genomics’ GBS platform provides dense genome-wide marker coverage, scalable multiplexing, and streamlined library preparation, supporting rapid and accurate genotyping across diverse species and accelerating genomic discovery.

In February 2023, NIMGenetics, a Spain-based provider of clinical genetic diagnostics, including genome and exome sequencing as well as precision medicine testing, acquired Gene Predictis for an undisclosed amount. Through this acquisition, NIMGenetics aims to expand its presence in Central Europe and strengthen its genomics-diagnostic offerings by enhancing preventive genetics and pharmacogenomics capabilities. Gene Predictis, a Switzerland-based company, specializes in precision medicine services, including polygenic risk scores, pharmacogenomics testing, and preventive-genetics solutions based on genotyping and genetic data interpretation.

Major companies operating in the genotyping market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, Eurofins Scientific SE, Agilent Technologies, PerkinElmer Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN NV, BGI Genomics, LGC Biosearch Technologies, GenScript Biotech, Inotiv, Takara Bio Inc., Integrated DNA Technologies Ltd., 23andMe Inc., Novogene Corporation, Oxford Nanopore Technologies, Macrogen Inc., Pacific Biosciences of California, Standard BioTools Inc., GENEWIZ, Transnetyx, Agena Bioscience Inc., Genotypic Technology Pvt Ltd., BMG LABTECH GmbH, Bioline, Biofortuna Limited, Xcelris Genomics.

North America was the largest region in genotyping market in 2025. The regions covered in the genotyping market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the genotyping market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the genotyping market by increasing costs of imported instruments, reagents, and genotyping kits. Pharmaceutical companies and research laboratories are most affected due to reliance on imported technologies. These tariffs raise testing costs by increasing assay and equipment expenses, potentially limiting high-throughput genotyping programs. However, they support domestic manufacturing of genetic testing tools, strengthening regional production of instruments and consumables.

The genotyping market research report is one of a series of new reports that provides genotyping market statistics, including genotyping industry global market size, regional shares, competitors with a genotyping market share, detailed genotyping market segments, market trends and opportunities, and any further data you may need to thrive in the genotyping industry. This genotyping market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Genotyping is a laboratory technique that examines an individual’s germline DNA to identify the presence of specific nucleotide or base variations. Through genotyping, researchers can investigate genetic variants such as single nucleotide variations, copy number variations, and large structural changes in DNA. This method is applied across diverse fields, including agriculture, medicine, and fundamental scientific research.

The main categories of genotyping products and services include instruments, reagents and kits, bioinformatics, and genotyping services. An instrument is a tool used to measure or analyze specific parameters, such as speed, height, or sound. In genotyping, instruments are employed to detect genetic variations, including large structural changes in DNA, copy number variations, and single nucleotide variations. The technologies used include microarrays, capillary electrophoresis, sequencing, polymerase chain reaction (PCR), matrix-assisted laser desorption/ionization (MALDI-TOF) mass spectrometry, and other techniques. These technologies are applied in areas such as pharmacogenomics, diagnostics and personalized medicine, animal genetics, agricultural biotechnology, and more. They are utilized by a variety of end users, including pharmaceutical and biopharmaceutical companies, diagnostic and research laboratories, academic institutions, and others.

The genotyping market consists of revenues earned by entities by providing services such as custom genotyping services, genetic counselling, genotyping assay services, Sanger sequencing, fragment length analysis, and genotyping data analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The genotyping market also includes sales of thermal cyclers, PCR (polymerase chain reaction) systems, fully integrated microarray instrument, which are used in providing genotyping services. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.